Looks Like Abbvie And Jeff Haas is kicking Gileads Ass. Go HAAS Go
Earlier Thursday, AbbVie reported a 79% increase in first-quarter Viekira Pak sales, to $414 million . AbbVie Inc. markets Viekira Pak, a competing and similarly costly treatment it launched in late 2014. Gilead has managed to protect much of its market share, but analysts have cautioned that pressure is heating up. “People are worried about the hepatitis C market,
Gilead Science Inc.'s earnings tumbled more than 17 percent in the first quarter as steeper discounts and rebates on its blockbuster hepatitis C drugs cut into sales.Gilead has become an unwilling poster-child for high drug prices, due to the staggering list prices for the hepatitis drugs: about $94,000 for Harvoni and $84,000 for Sovaldi. Insurers in the U.S. have demanded steep discounts — as much as 45 percent — to cover the two drugs, but their prices are straining budgets from the Veterans Affairs system to state Medicaid programs.
